Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedMar 27, 2026
DataAggregated Company Financials
Companies147
  • 7D2.5%
  • 3M-5.9%
  • 1Y-4.6%
  • YTD-5.2%

In the last week, the Healthcare industry is flat overall, with Medicover standing out by going down 6.5%. As for the longer term, the industry has declined 4.7% in the last year. Earnings are forecast to grow by 24% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 27 Mar 2026SEK 549.8bSEK 228.9b-SEK 2,601,221,027.2329.8x-211.3x2.4x
Sun, 22 Feb 2026SEK 569.3bSEK 229.3b-SEK 1,647,883,826.1131.3x-345.5x2.5x
Tue, 20 Jan 2026SEK 591.2bSEK 230.2bSEK 3.7b41.1x161.1x2.6x
Thu, 18 Dec 2025SEK 576.4bSEK 230.8bSEK 3.7b41x157.9x2.5x
Sat, 15 Nov 2025SEK 603.6bSEK 230.4bSEK 3.0b44.4x201.9x2.6x
Mon, 13 Oct 2025SEK 600.2bSEK 227.2bSEK 6.7b43.1x89.9x2.6x
Wed, 10 Sep 2025SEK 616.9bSEK 227.1bSEK 6.6b44.8x93.4x2.7x
Fri, 08 Aug 2025SEK 610.6bSEK 226.8bSEK 6.8b48.4x89.3x2.7x
Sun, 06 Jul 2025SEK 629.2bSEK 227.1bSEK 6.0b44.6x104.5x2.8x
Tue, 03 Jun 2025SEK 602.4bSEK 226.3bSEK 5.9b43.2x102.8x2.7x
Thu, 01 May 2025SEK 593.1bSEK 223.7bSEK 4.9b37x119.9x2.7x
Sat, 29 Mar 2025SEK 571.6bSEK 220.9bSEK 5.4b36.2x105.8x2.6x
Mon, 24 Feb 2025SEK 588.4bSEK 206.2bSEK 4.3b38.5x135.7x2.9x
Wed, 22 Jan 2025SEK 589.1bSEK 202.6b-SEK 2,463,435,869.4142x-239.1x2.9x
Fri, 20 Dec 2024SEK 573.1bSEK 202.6b-SEK 2,502,526,167.6538.6x-229x2.8x
Sun, 17 Nov 2024SEK 509.8bSEK 199.9b-SEK 2,849,689,856.4537.4x-178.9x2.5x
Tue, 15 Oct 2024SEK 539.1bSEK 195.3b-SEK 2,761,816,675.4638.6x-195.2x2.8x
Thu, 12 Sep 2024SEK 613.3bSEK 200.3b-SEK 2,805,459,044.7640.2x-218.6x3.1x
Sat, 10 Aug 2024SEK 573.5bSEK 199.5b-SEK 2,393,629,457.5740.8x-239.6x2.9x
Mon, 08 Jul 2024SEK 564.8bSEK 195.7b-SEK 3,195,314,032.7637.3x-176.8x2.9x
Wed, 05 Jun 2024SEK 566.7bSEK 195.7b-SEK 2,835,552,344.7736.3x-199.9x2.9x
Fri, 03 May 2024SEK 532.5bSEK 196.1b-SEK 3,326,882,163.3836.9x-160x2.7x
Sun, 31 Mar 2024SEK 527.3bSEK 192.9b-SEK 3,674,506,154.3846x-143.5x2.7x
Tue, 27 Feb 2024SEK 505.8bSEK 191.7b-SEK 3,873,204,956.9148.9x-130.6x2.6x
Thu, 25 Jan 2024SEK 549.6bSEK 191.7b-SEK 967,830,254.0050.8x-567.9x2.9x
Sat, 23 Dec 2023SEK 534.3bSEK 191.0b-SEK 960,279,085.0047.8x-556.4x2.8x
Mon, 20 Nov 2023SEK 489.3bSEK 190.1b-SEK 1,208,836,230.0047.3x-404.8x2.6x
Wed, 18 Oct 2023SEK 433.9bSEK 184.9b-SEK 1,976,085,302.0032.7x-219.6x2.3x
Fri, 15 Sep 2023SEK 454.9bSEK 185.7b-SEK 2,024,682,673.0036.5x-224.7x2.4x
Sun, 13 Aug 2023SEK 474.6bSEK 184.3b-SEK 1,014,174,020.0041.7x-468x2.6x
Tue, 11 Jul 2023SEK 475.7bSEK 179.4b-SEK 793,664,002.0044.1x-599.4x2.7x
Thu, 08 Jun 2023SEK 513.2bSEK 179.0b-SEK 543,106,564.0041.1x-944.9x2.9x
Sat, 06 May 2023SEK 530.4bSEK 176.4b-SEK 736,383,535.0041.1x-720.3x3x
Mon, 03 Apr 2023SEK 494.5bSEK 172.5b-SEK 1,399,898,502.0035.6x-353.2x2.9x
Price to Earnings Ratio

-353.2x


Total Market Cap: SEK 494.5bTotal Earnings: -SEK 1,399,898,502.00Total Revenue: SEK 172.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -164.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market-0.37%
Healthcare2.52%
Biotech5.38%
Medical Equipment2.64%
Life Sciences0.18%
Healthcare Services0.10%
Pharma-0.099%
Healthtech-2.05%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 116x.
    • Analysts are expecting annual earnings growth of 20.3%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 383.005.7%
+SEK 7.1b		30.6%PE277x
XVIVO Xvivo PerfusionSEK 226.0025.1%
+SEK 1.4b		-27.4%PE282.9x
BIOA B BioArcticSEK 317.204.8%
+SEK 1.3b		74.3%PE27.5x
ASKER Asker Healthcare GroupSEK 67.575.1%
+SEK 1.3b		-19.3%PE56.2x
GETI B GetingeSEK 187.002.5%
+SEK 1.2b		-15.2%PE22.6x

Latest News

MAGLE
SEK 4.26
Magle Chemoswed Holding
7D
-47.1%
1Y
-86.3%
ATT
SEK 100.80
Attendo
7D
-0.6%
1Y
66.1%
GETI B
SEK 187.00
Getinge
7D
2.5%
1Y
-15.2%

GETI B: Dividend Proposal Will Support Confidence Despite Lower Margin Assumptions

Analysts have lowered their price target for Getinge to SEK270 from SEK300, citing updated assumptions that include a higher discount rate, a lower projected profit margin, and a slightly higher future P/E multiple and revenue growth outlook. What's in the News Getinge AB has a proposal for a dividend of SEK 4.75 per share to be decided at its Annual General Meeting on April 21, 2026, with a proposed record date of April 23, 2026 (Key Developments).
ALIF B
SEK 136.80
AddLife
7D
-0.9%
1Y
-8.8%

ALIF B: Higher Margin Outlook And Dividend Policy Will Support Future Upside

Analysts have trimmed their price target for AddLife from SEK191.50 to SEK187.50, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E levels. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.5000 per share, with an ex date on May 7, 2026, a record date on May 8, 2026, and a payment date on May 13, 2026 (Key Developments).
BIOA B
SEK 317.20
BioArctic
7D
4.8%
1Y
74.3%

BIOA B: Future Earnings Will Depend On High China Access Risk

Analysts have nudged their fair value estimate for BioArctic to SEK240 from SEK236. This reflects updated assumptions around revenue contraction, profitability and a higher future P/E multiple, while keeping the discount rate broadly similar.
XVIVO
SEK 226.00
Xvivo Perfusion
7D
25.1%
1Y
-27.4%

XVIVO: Higher Margins And Discount Assumptions Will Support Future Upside Potential

Analysts have modestly reduced their price target for Xvivo Perfusion to SEK245. This reflects slightly higher discount rate assumptions alongside small adjustments to revenue growth, profit margin, and future P/E expectations.
BONEX
SEK 188.20
Bonesupport Holding
7D
5.2%
1Y
-37.4%

BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential

Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.
RAY B
SEK 185.00
RaySearch Laboratories
7D
-1.4%
1Y
-19.9%

RAY B: Dividend Commitment And Adaptive Therapy Adoption Will Support Stronger Outlook

Analysts have maintained their price target for RaySearch Laboratories at SEK 330. Small adjustments to the discount rate, long-term revenue growth, profit margin and future P/E assumptions have led them to conclude that the previous valuation remains appropriate.
MCOV B
SEK 187.20
Medicover
7D
-4.3%
1Y
-4.2%

MCOV B: Dividend Policy And 2028 Revenue Ambition Will Drive Future Upside

Analysts have trimmed their Medicover price target from SEK 325 to SEK 307 as updates to fair value, discount rate, revenue growth, profit margin assumptions and expected future P/E filter through their models. What's in the News The board proposes a dividend of SEK 0.20 per share for the 2025 financial year, up from SEK 0.15, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).
VIMIAN
SEK 26.90
Vimian Group
7D
3.6%
1Y
-33.7%
SECT B
SEK 224.00
Sectra
7D
-2.4%
1Y
-9.4%

SECT B: Cloud Deals And Rating Upgrades Will Shape Balanced Return Profile

Sectra's analyst price target has been revised from SEK 220 to about SEK 228. Analysts have issued refreshed Buy ratings and higher targets in the SEK 210 to SEK 250 range that reflect updated views on growth, profitability and future P/E assumptions.
SOBI
SEK 383.00
Swedish Orphan Biovitrum
7D
5.7%
1Y
30.6%

SOBI: Kidney And Sepsis Progress Will Support A More Constructive Outlook

Analyst price targets for Swedish Orphan Biovitrum have moved higher toward SEK 470 to SEK 500, as analysts highlight their updated views following recent rating changes and an upgraded stance from several firms. Analyst Commentary Recent research updates on Swedish Orphan Biovitrum show a mix of optimism around upside potential and some caution on how much of that is already reflected in the share price.
EKTA B
SEK 55.55
Elekta
7D
-2.0%
1Y
2.4%

EKTA B: Rising Margin Outlook And New Clearance Will Support Medium Term Upside

Analysts have nudged their price targets for Elekta higher, with one recent move taking the target to SEK 60 from SEK 49. This reflects updated views on fair value, discount rates, profit margins and future P/E assumptions.
VITR
SEK 92.85
Vitrolife
7D
5.6%
1Y
-42.4%
ASKER
SEK 67.57
Asker Healthcare Group
7D
5.1%
1Y
-19.3%
DICOT
SEK 0.40
Dicot Pharma
7D
-8.5%
1Y
32.2%

Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?

Feb 03
Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?